Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605287751> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2605287751 endingPage "1510" @default.
- W2605287751 startingPage "1510" @default.
- W2605287751 abstract "1510 Background: We update this trial evaluating ZD-1839(Iressa) for treatment of malignant gliomas recurring after radiation therapy and for unresectable benign or anaplastic meningiomas (MEN) progressing after radiation therapy. Methods: In the phase II component, patients who were not receiving enzyme inducing anticonvulsants (EIAED) or corticosteroids, were treated with 500mg/ day. The dose in patients receiving corticosteroids was escalated in two increments of 250mg to 1000mg/day. Phase II study was limited to patients with 2 or less relapses. For patients on EIAEDs, a phase 1 component began at 500mg/day and was escalating in 250mg increments. Subjects in the phase 2 component were evaluated for radiological response, time to progression (TTP), and percentage without progression at 6 months (%PFS-26wk). Results: The MTD for patients on EIAEDs is 1500mg/day. As of 11/19/03, 38 glioblastoma(GBM), 17 anaplastic glioma(AG), and 10 MEN patients had entered phase 2 study. The median TTP for GBM is unchanged at 8 weeks (95%CI:7–12weeks). The median TTP for AG is shortened at 12 weeks (95%CI:7-ND). For both GBM and AG, %PFS-26wk is unchanged at 9%(95%CI:3–27%), and 33%(95%CI: 13–81%). However, 1 GBM patient had SD for 66wks, and 1 is progression free at 93 wks; 4 AG patients had SD for over 50wks. Partial responses (not centrally confirmed) were seen in 5 GBM, 1 AO and 1 anaplastic oligoastrocytoma. No MEN has responed. Skin rash, transaminase elevations, fatigue, diarrhea, and hypokalemia were the most common toxicities. No pulmonary interstitial fibrosis was observed. Conclusion: The MTD for ZD-1839 in patients receiving EIAEDs is 1500mg/day. With complete accrual in both GBM and AG cohorts, ZD-1839 does not prolong TTP compared to historical controls, but subgroups of both GBM and AG demonstrated prolonged TTP. Microdisection based genotyping and determination of EGFR expression is in progress to determine if these tumors are distinguishable from those demonstrating rapid progression. No significant financial relationships to disclose." @default.
- W2605287751 created "2017-04-14" @default.
- W2605287751 creator A5014264452 @default.
- W2605287751 creator A5019353782 @default.
- W2605287751 creator A5030409076 @default.
- W2605287751 creator A5045925835 @default.
- W2605287751 creator A5050461270 @default.
- W2605287751 creator A5061018141 @default.
- W2605287751 creator A5069589435 @default.
- W2605287751 creator A5075492015 @default.
- W2605287751 creator A5077543635 @default.
- W2605287751 creator A5080942029 @default.
- W2605287751 date "2004-07-15" @default.
- W2605287751 modified "2023-10-06" @default.
- W2605287751 title "NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas" @default.
- W2605287751 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.1510" @default.
- W2605287751 hasPublicationYear "2004" @default.
- W2605287751 type Work @default.
- W2605287751 sameAs 2605287751 @default.
- W2605287751 citedByCount "22" @default.
- W2605287751 countsByYear W26052877512012 @default.
- W2605287751 crossrefType "journal-article" @default.
- W2605287751 hasAuthorship W2605287751A5014264452 @default.
- W2605287751 hasAuthorship W2605287751A5019353782 @default.
- W2605287751 hasAuthorship W2605287751A5030409076 @default.
- W2605287751 hasAuthorship W2605287751A5045925835 @default.
- W2605287751 hasAuthorship W2605287751A5050461270 @default.
- W2605287751 hasAuthorship W2605287751A5061018141 @default.
- W2605287751 hasAuthorship W2605287751A5069589435 @default.
- W2605287751 hasAuthorship W2605287751A5075492015 @default.
- W2605287751 hasAuthorship W2605287751A5077543635 @default.
- W2605287751 hasAuthorship W2605287751A5080942029 @default.
- W2605287751 hasConcept C126322002 @default.
- W2605287751 hasConcept C141071460 @default.
- W2605287751 hasConcept C2776694085 @default.
- W2605287751 hasConcept C2778227246 @default.
- W2605287751 hasConcept C2778242168 @default.
- W2605287751 hasConcept C2778570526 @default.
- W2605287751 hasConcept C2780739268 @default.
- W2605287751 hasConcept C31760486 @default.
- W2605287751 hasConcept C502942594 @default.
- W2605287751 hasConcept C509974204 @default.
- W2605287751 hasConcept C71924100 @default.
- W2605287751 hasConcept C90924648 @default.
- W2605287751 hasConceptScore W2605287751C126322002 @default.
- W2605287751 hasConceptScore W2605287751C141071460 @default.
- W2605287751 hasConceptScore W2605287751C2776694085 @default.
- W2605287751 hasConceptScore W2605287751C2778227246 @default.
- W2605287751 hasConceptScore W2605287751C2778242168 @default.
- W2605287751 hasConceptScore W2605287751C2778570526 @default.
- W2605287751 hasConceptScore W2605287751C2780739268 @default.
- W2605287751 hasConceptScore W2605287751C31760486 @default.
- W2605287751 hasConceptScore W2605287751C502942594 @default.
- W2605287751 hasConceptScore W2605287751C509974204 @default.
- W2605287751 hasConceptScore W2605287751C71924100 @default.
- W2605287751 hasConceptScore W2605287751C90924648 @default.
- W2605287751 hasIssue "14_suppl" @default.
- W2605287751 hasLocation W26052877511 @default.
- W2605287751 hasOpenAccess W2605287751 @default.
- W2605287751 hasPrimaryLocation W26052877511 @default.
- W2605287751 hasRelatedWork W1586374228 @default.
- W2605287751 hasRelatedWork W2003938723 @default.
- W2605287751 hasRelatedWork W2047967234 @default.
- W2605287751 hasRelatedWork W2118496982 @default.
- W2605287751 hasRelatedWork W2347438058 @default.
- W2605287751 hasRelatedWork W2364998975 @default.
- W2605287751 hasRelatedWork W2369162477 @default.
- W2605287751 hasRelatedWork W2439875401 @default.
- W2605287751 hasRelatedWork W4238867864 @default.
- W2605287751 hasRelatedWork W2525756941 @default.
- W2605287751 hasVolume "22" @default.
- W2605287751 isParatext "false" @default.
- W2605287751 isRetracted "false" @default.
- W2605287751 magId "2605287751" @default.
- W2605287751 workType "article" @default.